Confirmatory study of EN-P09 in patients with enteral tube feeding.

EN Otsuka Pharmaceutical Co., Ltd.0 个研究点目标入组 110 人开始时间: 2021年9月5日最近更新: 2024年9月25日

试验速览

暂无简介。

•Patients receiving enteral feeding via a gastrostomy into the stomach.
•Patients able to stay at the study site from the day before the start of the run-in observation period until completion of post-dosing examination.
•Patients aged 20 years old or more.
•Patients or the legal representative capable of giving informed consent in wrtiting to participate in the study of their own free will.

•Patients with a history of hypersensitivity to any ingredients of study drugs.
•Patients with a history of allergy to milk protein.
•Patients with no residual gastric or intestinal function.
•Patients with ileus.
•Patients with severe liver or renal dysfunction (example: acute or chronic renal failure, or cirrhosis).
•Patients with abnormalities in carbohydrate metabolism including severe diabetes mellitus.
•Patients with congenital abnormalities in amino acid metabolism.
•Patients with severe heart disease (example: myocardial infarction), severe hematological disorder (example: aplastic anemia), inflammatory bowel disease, pneumonia, serious diarrhea (example: frequent watery diarrhea), and patients with malignant tumor.
•Patients with a history of resection of esophagus or stomach, except for minimally invasive surgery such as endoscopic submucosal dissection.
•Patients with a history of resection of intestines within 1 year before obtaining informed consent , except for slight removal like polyp or appendectomy.
•Patients with difficulties in taking required amount of blood sample for clinical trial.
•Patients participated in other clinical trials within 24weeks before obtaining informed consent.
•Patients who are judged by investigator to be excluded.

Tansthyretin, Retinol-binding protein, Transferrin.

未报告次要终点

发起方